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Type 1 diabetes (T1D), an autoimmune disease which destroys the pancreatic islets resulting in 
insulin deficiency, often begins early in life when islet autoantibody appearance signals high 
risk1. However, clinical diabetes can follow in weeks or only after decades, and is very difficult 
to predict.  Ketoacidosis at onset remains common2,3 and is most severe in the very young4,5 
where it can be life-threatening and difficult to treat6–9.  Autoantibody surveillance programs 
effectively prevent most ketoacidosis10–12 but require frequent evaluations whose expense 
limits public health adoption13.  Prevention therapies applied before onset when greater islet 
mass remains, have rarely been feasible14 because individuals at greatest risk of impending T1D 
are difficult to identify.  To remedy this, we sought accurate, cost-effective estimation of future 
T1D risk by developing a Combined Risk Score (CRS) incorporating both fixed and variable 
factors (genetic, clinical and immunological) in 7,798 high-risk children followed closely from 
birth for 9.3 years. Compared to autoantibodies alone, the combined model dramatically 
improves T1D prediction at ages ≥2 over horizons up to 8 years (ROC-AUC ≥0.9), doubles the 
estimated efficiency of population-based newborn screening to prevent ketoacidosis, and 
enables individualized risk estimates for better prevention trial selection. 
 
T1D is associated with significant heritable risk, notably from common HLA variants but also 
from many diverse genetic loci15.  Environmental factors increase the risk16.  Recent attempts to 
predict who will develop T1D and at what age, have used islet autoantibodies (AB)17,18, 
metabolic status19,20, genetic factors21–25 and family history (FH)26.  Longitudinal AB 
measurement has been established as the strongest single predictor of future T1D in first 
degree relatives18 or in general populations either unselected27 or prescreened for genetic 
risk1,18,28. Combined assessment of both fixed and time-varying risk factors improves both 
prediction of T1D progression in first degree relatives20,21,23–25 and the accuracy of diabetes 
diagnoses in adult incident cases22. However, no T1D screening or prediction efforts to date 
have taken full advantage of the complementary information that age, genetic risk, FH and 
environmental factors offer, when combined with AB status, to estimate future T1D risk in all 
children. Such combined modeling could significantly improve prediction of T1D and other 
childhood diseases throughout early life by allowing risk assessments to reflect each individual’s 
specific age and situation.  
   
  




The Environmental Determinants of Diabetes in the Young (TEDDY) study screened 425,000 
children from the USA, Sweden, Germany and Finland and prospectively studied 8,676 from 
birth through age 15 years29. Participants received frequent AB and exposure testing, in 
addition to physiological and clinical measurements. We used TEDDY data to develop a model 
predicting T1D during the first 10 years of life.  We considered features known to indicate 
increased T1D risk, including a recently published T1D genetic risk score(GRS2)30, longitudinal 
AB measurements, and a variety of other medical, demographic and environmental factors31.  
This rich dataset enabled us to develop a Combined Risk Score (CRS), targeting children with 




Multiple variables are predictive of childhood T1D in univariate analyses of TEDDY data 
(Extended Data 1)32,33. These include FH in first-degree relatives, presence of AB, the T1D 
GRS230, the weight z-score at age 1, sinusitis episodes and country of residence.  By age 2, AB 
are already highly predictive, with a time-dependent ROC AUC of 0.75 (95% CI 0.71-0.78). The 
GRS2 alone had an AUC of 0.73 (0.70-0.77) despite use in a highly HLA-selected cohort where 
94% of the TEDDY cohort had a GRS2 value in the top 20th percentile of a control population. 
We chose GRS2 because it performed best in TEDDY and other datasets30 compared to similar 
genetic risk scores (Extended Data 2 and Methods). Other T1D-associated variables such as FH, 
weight z-score, sinusitis episodes and country of residence were far less predictive (ROC AUCs 
of 0.51-0.56). 
 
We determined which combination of associated variables from Extended Data 1 best 
predicted future T1D at each landmark age using stepwise selection. Overall, a 3-variable, CRS 
incorporating AB, GRS2 and FH, performed best in cross-validated time-dependent ROC-AUC 
(Figure 1) and using the Akaike information criterion (AIC). ROC-AUC were all ≥0.92 for 
landmarks ≥2 years and horizons up to 5 years. When compared to a model using all 6 
associated variables, the 3-variable model performed equally well (Figure 2).  
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We tested whether additional variables might be eliminated from the 3-variable CRS model. 
Models with GRS2 and FH outperformed GRS2 alone (Extended Data 3). We asked if a 3-
variable CRS was better than AB alone, the latter being the most established approach for T1D 
prediction. The 3-variable score outperformed AB status alone in univariate Cox regression 
using AIC, again with higher ROC AUCs upon cross validation (Extended Data 4). This effect was 
greatest at landmark age 2 for all time horizons (Figure 2a) but also was clear at landmark age 4 
for longer horizons (Figure 2b). Nevertheless, when present, AB do confer greater hazard ratios 
for T1D than GRS2 or FH components (Extended Data 5). The CRS appears to help most for 
children not yet with AB or with only one AB (right side of ROC curve in Figure 2 and Extended 
Data 6 respectively).  In TEDDY at age 2 years, 38% of children subsequently developing T1D 
during follow-up to a median age of 9.3 years, will have <2 AB.  
 
The 3-variable CRS discrimination in this cohort corresponded to well-separated T1D and non-
T1D populations in the plotted distributions of the 3-variable CRS.  The bimodal CRS distribution 
among future T1D cases reflects the model’s AB term, since many already have ≥1 AB by 
landmark age 2 (Figure 3a) and even more by age 4 (Figure 3b).  Calibration plots for the 3-
variable model with the same 2- and 4-year landmarks (Figures 3c and 3d, respectively) indicate 
that an increasing CRS generally corresponds to an increasing actual risk of future T1D, with a 
mild tendency to underestimate disease risk of children at midrange probabilities. 
 
We generated T1D progression risk estimates for individual children based on the 3-variable 
T1D CRS model, using a 2-year landmark age (Extended Data 7).  At moderately high GRS2 (the 
90th percentile of a background population using UK Biobank) and without FH, the risk of T1D 
in the next 5 years increases by ~14% with one AB and by ~42% with two AB.  Conversely, for a 
given number of AB, FH and GRS2 increase risk five-fold when comparing moderately high GRS2 
with no FH, to very high GRS2 with a positive FH (Extended Data 7 and Supplementary Table 1). 
 
Using TEDDY data, we modeled three population-based screening strategies in incident cases 
diagnosed by age 10 from among all originally screened newborns (Figure 4). Each was adjusted 
to achieve a comparable (75%) rate of identification of very high risk ≥4 weeks before onset. 
The first “Classic” strategy initially selected infants with high GRS2 genetic risk, and followed 
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them closely (defined as quarterly until age 3, then every 6 months until age 6, and then every 
year thereafter until age 8). The second “Simple Adaptive” strategy selected infants with high 
genetic risk, followed them closely, but then recalculated the T1D CRS at annual landmarks. At 
each landmark, any child with T1D probability by age 10 years of P<0.008 was eliminated from 
further follow-up. The third “Advanced Adaptive” strategy also selected newborn infants at 
high genetic risk, but then annually recalculated the T1D CRS to reallocate children between a 
close follow-up group and a reduced follow-up group. Reallocation was based on a calculated 
T1D probability in the next 2 years of ≥0.006 or <0.006, respectively.  
 
The endpoint of these prediction strategies, via the CRS, is the estimated percentage risk of T1D 
onset over the stated time horizons. This guides the approach to the family regarding the risk of 
impending T1D onset in their child, the follow-up schedule for the child in the two adaptive 
strategies, and the consideration of prevention therapies.  Although related, it is distinct from 
the more commonly used T1D prediction endpoint of islet autoantibodies.  
 
Consistent with requirements of the 3-variable CRS, each follow-up evaluation updates status of 
three AB (GADA, IA2A and IAA) and T1D family history.  We compared the total number of 
follow-up evaluations required under each strategy to achieve our goal of 75% advance 
identification of new onset cases.  Adaptive strategies utilizing the 3-variable T1D CRS required 
25% and 51% fewer surveillance evaluations, respectively, compared to the standard strategy 
(Extended Data 8, Extended Data 9). 
 
Effectively, the CRS identifies children requiring frequent evaluation in order to predict 
impending T1D onset. This includes even children with no AB who nonetheless may be at high 
risk of early onset. For example, if children are not closely followed from birth to age 1, then 10 
children would not be warned before T1D onset, but this falls to 2/10 or 0/10 using the 
advanced or simple adaptive strategies, respectively. Similarly, if only AB positives are followed 
quarterly from age 1 to 2, with others followed yearly, then 11/36 children developing T1D 
during this year would not receive advanced warning to prevent ketoacidosis. This number falls 
to 4/36 using the advanced adaptative strategy and 0/36 for the simple adaptative strategy, 
important improvements at these vulnerable ages. 
   
  






Our results using family history, genotyped risk and autoantibodies, highlight that the most 
accurate disease prediction, particularly of complex disease, will come from integration of 
multiple risk factors. This has been demonstrated in other settings (e.g. Q risk34) but our 
approach is novel for a complex childhood disease. It is notable that exposures such as sinusitis, 
weight and residence country33, while significant when considered alone, did not appear to add 
predictive value in a combined model.  Using only 3 variables in our final model lessens the 
possibility of overfitting, while also minimizing information collection at follow-up evaluations.  
 
An increasing area of interest is whether prediction of common, complex pediatric diseases can 
provide practical health benefit at a population level. The identification of babies with rare, 
treatable diseases, such as PKU (phenylketonuria), by post-natal heel prick testing is 
commonplace in modern healthcare systems, and early treatment is life changing35.  For T1D, 
the most life-threatening complication is DKA in the very young, which can lead to serious 
neurological complications and incurs high treatment costs. Detection of islet-specific AB before 
onset allows advance warning and close monitoring which lessens the incidence of DKA10–12. 
Successful advance warning in infants requires AB surveillance to start early in life and to occur 
frequently, since progression from AB positivity to hyperglycemia is most rapid in infants1,36.  
 
Without a genotyping component, T1D risk prediction either requires surveillance of too many 
children or requires selection by family history which miss most cases.  Substituting a polygenic 
GRS for more commonly used HLA genotypes, and then combining this information with other 
variables into a CRS for adaptive surveillance, greatly improves efficiency and therefore may 
allow reconsideration of public health-based newborn screening for T1D and related 
autoimmune diseases.  In this setting, the ability of the CRS to provide accurate individual risk 
estimates is an important added benefit, although it must be carefully explained that not all 
children identified as “at high risk” will develop childhood T1D37. 
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Greater precision in identifying individuals at high risk of impending T1D will greatly improve 
the cost and feasibility of early life intervention trials, such as those testing expensive 
vaccines14,38, by reducing the number of participants needed to appropriately power early stage 
studies24,30. It could also lessen potential exposure to immunosupressive drugs in children less 
likely to develop T1D.  Finally, it opens the possibility of earlier disease mitigation before 
dysglycemia appears and when more functioning beta cells remain. 
 
Our study has several limitations.  TEDDY, like many birth cohort studies of T1D, preselected 
newborns at high HLA risk in order to observe sufficient disease endpoints to achieve study 
goals.  After removal of these HLA effects, the remaining difference in genetic risk is much 
smaller between TEDDY children who developed T1D and those who did not (Extended data 
10). Therefore, the CRS yields a lower calculated AUC ROC at landmarks <2 years of age (Figure 
1) than would be expected during general population use.  In both T1DGC and UK BioBank 
cohorts30, the GRS2 alone had an AUC ROC >0.92 for T1D. This implies that a 3-variable CRS 
incorporating GRS2 may have greater ROC AUC’s at young ages in an unselected pediatric 
population than in TEDDY.  However, validating the model on children with a wide range of 
GRS2 risk awaits the availability of such a dataset.  On another note, subtle abnormalities in 
blood glucose levels by a variety of measures are emerging as an important marker of T1D 
progression close to diagnosis19.  These are not typically measured in prediabetes, and were not 
measured in children lacking multiple AB in TEDDY, and so cannot be included in our model.  
Also, the CRS model was less discriminant among children with 2 or more AB.  Larger studies 
with more power are needed to study this specific group at very young ages.  Finally, the 
modeled genes and environmental features common to European and US populations may 
perform differently in other populations with distinct genetic backgrounds or environments.  
Analyses to date in other cohorts suggest that GRS2 should perform well in the all major USA 
ethnicities39 and that AB are similarly predictive in this regard40.   Along these lines, the model 
validated well when tested in the TEDDY data from each single country using the other three 
countries to fit the model (Supplementary Table 2).  However, to fully address these concerns, 
external validation in other birth cohorts is an essential next step. 
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TEDDY is a prospective cohort study designed to identify environmental causes of T1D41. From 
2004 to 2010, 424,788 newborns were screened at six US and European centers for high risk 
HLA genotypes. TEDDY then enrolled 8,676 eligible infants with the intent to follow until age 15 
years. The three major eligible HLA-DR-DQ haplotypes are DR3-DQA1*0501-DQB1*0201, DR4-
DQA1*0301-DQB1*0302 and DR8-DQA1*0401-DQB1*0402. These are referred to by their DR 
haplotypes and form the four TEDDY-eligible haplogenotypes DR3/4, DR4/4, DR4/8 and DR3/3. 
Frequencies of all eligible HLA haplogenotypes for each center are published42. Historical data 
from the TEDDY centers suggest that ~50% of childhood T1D cases carry one of these four 
included haplogenotypes.  
 
TEDDY children were followed prospectively from age 3-4 months, with visits every 3 months 
until age 4 years. Each evaluation tested the three islet antibodies (GADA, IA2A and IAA), 
changes in family history, as well as other measurements specified by the TEDDY protocol.  
After age 4, children with any islet autoantibody (AB) remained on quarterly visits, while 
antibody-negative children were evaluated every 6 months. Of 8,676 TEDDY enrollees, 7,883 
were analyzed herein on the basis of full AB testing, SNP genotyping on the ImmunoChip array, 
and carrying one of the four major TEDDY eligible HLA haplogenotypes. At the time of analysis, 
median follow-up was 9.3 years (range 1-168 months, interquartile range [IQR] 54 to 132 
months) covering 65,331 person-years of observation. Children are followed prospectively until 
age 15, or until T1D onset defined using the American Diabetes Association’s criteria for 
diagnosis41. In this dataset, 305 children developed T1D. Local Institutional Review Board 
approval, parental informed consent, and child assent where relevant, were obtained for all 
participants without exception. The study is also monitored by an External Evaluation 
Committee of the U.S. National Institutes of Health.  
 
The TEDDY Study measures a wide range of background information and environmental 
exposures on the cohort.  Background information includes self-reported race and ethnicity, 
geographic residence country, and TEDDY Clinical Center. TEDDY registers family history of T1D 
   
  
   
 
12 
in the mother, father or sibling. Medical history includes pregnancy factors such as infections 
and Caesarian-section, and childhood factors such as medications and illnesses. Parental 
questionnaires captured incidence of the child’s febrile illnesses, respiratory infections 
(common cold, sinus infection, ear infection, bronchitis, pneumonia) and gastrointestinal 
infections43. Serum collected at each clinic visit was analyzed for the presence of autoantibodies 
to glutamic acid decarboxylase (GADA), insulinoma antigen-2 (IA-2A) and insulin (IAA) in two 
separate core laboratories by using harmonized radiobinding assays incorporating extensive 
quality control44. Only persistent autoantibodies, positive for the same antigen confirmed by 
both core laboratories in two consecutive samples, are considered in the current analyses. 
 
Generation of the T1D Genetic Risk Score.  TEDDY cohort children were genotyped on the 
Illumina Infinium ImmunoChip Single Nucleotide Polymorphism (SNP) array45. Prior to 
imputation, SNP variant quality control filtered on SNP genotype missingness (<1%), Hardy-
Weinberg equilibrium (HWE) (p<1x10-6) and minor allele frequency (<1%). For variants in HLA 
(chromosome 6: 27Mbp – 35Mbp), due to the HLA-based cohort selection42, we omitted HWE-
based filtering in order to retain key variants. Sample quality control checks for sex discordance, 
individual genotype missingness (<1%) and principal components analysis, resulted in exclusion 
of 85 subjects. After quality control, 167,350 SNPs and 7,798 individuals were available for 
analysis. The ImmunoChip data was then imputed to the 1000 Genomes reference panel, 
yielding 37.1 million SNPs at imputation quality >0.8. Independent of this TEDDY dataset, we 
have described three T1D genetic risk scores, our original 30-SNP T1D GRS22, the 40-SNP 
combined TEDDY GRS21 and a recently published more comprehensive 67-SNP T1D GRS230. The 
latter was newly generated in TEDDY for this analysis. Most of the GRS2 SNPs were genotyped 
directly, but 21 were imputed with r2≥0.75 and 4 were imputed with r2=0.358-0.544 
(Supplementary table 3). These SNP genotypes were used to generate continuous numerical 
risk score values for GRS2. 
 
Variable selection.  A broad list of features was evaluated for potential use in a CRS. We 
evaluated whether incorporating features that change in an individual over time (for example, 
the development of AB) along with fixed characteristics like GRS, could improve prediction of 
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future T1D risk. All were required to be available in a typical clinical setting, such as initial 
genetic screening for a panel of SNP markers followed by a standard blood sample and medical 
history during each follow-up evaluation. To reduce the chance of false discovery and 
overfitting, we also required each variable to be previously established as associated with T1D 
in published TEDDY analyses and in the background literature (Extended Data 1). The number of 
diabetic and nondiabetic children in each of these variable categories is shown in 
(Supplementary table 4).  
 
Simplification of risk factors. We combined T1D in a sibling, father, or mother, to a combined 
“any first degree relative with T1D” variable denoted FH. Likewise we combined the GADA, 
IA2A, and IAA variables to a single variable representing the number of persistent islet 
autoantibodies (denoted AB). We then compared the model performance using each summary 
variable versus that using all of the corresponding fully detailed variables. The summary 
variables, FH and AB, were each equally informative as their individual components (data not 
shown). GRS230 outperformed prior GRS used in TEDDY21 and elsewhere22 at all landmarks and 
horizon time prediction, with an average univariate AUC of 0.73 versus 0.63 (Extended data 2). 
Therefore, only GRS2 was considered in our modeling, which left us with 6 variables to consider 
(FH, AB, GRS2, weight z-score, sinusitis episodes and residence country). 
 
Combined Risk Score Model Construction.  We used an approach where CRS generation 
occurred at a fixed time points at and after birth, using all information available up to that time. 
Participants were assumed negative for islet autoantibodies at birth based on extrapolation 
from published TEDDY incidence data46. The score was revised at each later time point as 
information became updated. This approach has been termed “landmarking”47,48 and takes 
advantage of the TEDDY study design, where risk factors are measured repeatedly on an 
individual at different time points during childhood. Only patients without T1D at the landmark 
age of interest are included in analyses. The visit was assigned to occur at the formal visit age if 
it complied with the protocol-approved visit window. Landmark ages selected were at different 
visits time: birth, 1, 1.5, 2, 3, 4, 5, 6 and 8 years of age, representing 9 different models. 
Another important feature of survival analyses is the future prediction time interval after the 
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landmark, termed the “horizon” time. For example, a landmark at 2 years and horizon time of 5 
years, means that we aim to predict if a child will develop T1D by age 7 using a CRS generated 
on a non-diabetic child at age 2. Horizon times used in this study were 1, 3, 5 and 8 years. 
 
The Combined Risk Scores (CRS) were generated using a Cox regression model. Our goal was to 
maximize the predictive accuracy while minimizing the number of variables required. At each 
landmark, we initially selected variables which were independently significant using the Wald 
test49.  At each landmark, we sought to find the best combination of variables to predict T1D, by 
performing bidirectional stepwise selection with the Bayesian information criterion (BIC)50. 
 
Model evaluation.  Since TEDDY is a prospective cohort study where participants progress to 
T1D over time and are subject to censoring, time dependency must be incorporated into the 
predictive assessment of the CRS. We used time-dependent analysis of ROC AUC51 to evaluate 
model performance at the various landmark ages and horizon times. We used 3-fold cross 
validation (repeated 10 times) to assess model precision and to reduce overestimation of 
model performance. To compare models we used the R timeROC package developed by 
Blanche et al51.  Overall, we selected a set of variables that gave optimal prediction at the 
various landmarks and horizon times according to the best average AUC derived by cross-
validation. 
 
Screening Simulation.  We compared a strategy of selecting high risk children from birth and 
following them all, irrespective of their changing probability of T1D (classic strategy), versus two 
strategies that allowed us to either stop (simple adaptive) or to modulate (advanced adaptive) 
later follow-up visits in those individuals with lower probability of T1D.  Our goal was to test if 
we could detect the same number of childhood T1D cases (75%) with fewer follow-up visits 
using one of the latter strategies. The three strategies are detailed in Figure 4. 
 
We used UK Biobank to estimate, for initial newborn screening, T1D GRS2 cutoff values which 
achieved various targets for proportion of future cases included in the “initially followed 
cohort”. This is described in the first table in the published description of the GRS230. These 
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specific target proportions were matched to the specific sensitivities of the follow-up 
performance of each overall strategy, to achieve a net 75% pre-onset case detection. 
 
For follow-up, our baseline schedule comprised quarterly evaluations through age 3, then every 
6 months until age 6, and then annually thereafter. This strategy was chosen because TEDDY 
included samples at each of these ages, and for the TEDDY cohort, using this schedule missed 
very few children.  In TEDDY, all high risk children remain in follow up, this schedule misses very 
few children with a median of 51 days (IQR (84-18.5), range 1-384) time from last visit to T1D 
presentation. 
 
The classic strategy used this baseline follow-up schedule. The simple adaptive strategy also 
used the baseline follow-up schedule in all children remaining in follow-up. The advanced 
adaptive strategy used the baseline follow-up strategy for those children in the close follow-up 
subgroup, but annual follow-up for those in the reduced follow-up subgroup.  Each follow-up 
strategy was separately simulated over the TEDDY dataset.  We compensated for right 
censoring in TEDDY data by using inverse weighting estimator.  
The optimum cut-offs for initial genetic inclusion and for retention or reassignment in the 
surveillance group, were chosen using a grid optimization. We selected the cut-off among the 
values from 0.001 to 0.01 with steps of 0.001 to determine the optimum value, defined as that 
minimizing the number of follow-up evaluations while ensuring that 75% of the population 
cases had an adequate follow-up. Optimization was performed independently for each design 
strategy.  For the simple adaptive strategy it led to a CRS landmark cutoff of T1D probability 
≥0.006 (up to the age of 10) for continued follow-up, which required 10.7% of the screened 
newborn population to be included in the initially followed cohort. For the advanced adaptive 
strategy, it led to a CRS landmark cutoff of 2 year T1D probability ≥0.008 for assignment to the 
frequently followed subgroup, which required 11.2% of screened newborns to be included in 
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Figure Legends Main Text 
 
Figure 1:  Summary of time dependent ROC AUCs for the 3-variable model by age at 
prediction scoring, and at four different prediction horizons as denoted by color. The vertical 
dotted line corresponds to the landmark age of 2 years featured in Figure 2 Panel a. 
 
Figure 2:  Panel a: ROC curves derived from models using all 6-variables (dotted line), 3-
variables (solid line) or autoantibodies only (dashed line). All used a landmark age of 2 years 
and a prediction horizon of 3 or 8 years as indicated.  
 Panel b: ROC curves derived from models using all 6-variables (dotted line), 3-
variables (solid line) or autoantibodies only (dashed line). All used a landmark age of 4 years 
and a prediction horizon of 3 or 8 years as indicated.  
 
Figure 3:  Panels a and b: score distribution for 3-variable model at a horizon time of 5 
years for a) landmark at 2 year, b) landmark at 4 years with increases in AUC ROC as noted 
on the figure. The T1D CRS was generated by the linear predictor of the parametric part of 
the hazard function of the Cox model. 
Panels c and d: calibration plot for 3-variable model at a horizon time of 5 years 
and c) landmark at 2 years and d) landmark at 4 years. The predictions are grouped into 
centiles based on their predicted values, and then the bin prevalence (the ratio of plots in 
this bin with observed values of present versus the total number of plots in this bin) is 
calculated for each bin. 
 
 
Figure 4:  Three strategies for population-based newborn screening, the latter two using the 
3-variable T1D CRS to dynamically define the follow-up schedule for individuals in the cohort. 
The models are termed a) “Classic”, b) “Simple Adaptive”, and c) “Advanced Adaptive”. 
 
*Risk is recalculated annually during the first 4 years life, then every 2 years thereafter. 
**Close follow-up is quarterly to age 3, then biannually to age 6, then annually to age 8.  
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   Reduced follow-up is annually to age 4 then every two years. 
